JP Morgan Chase’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-18,500
| Closed | -$29.4K | – | 7888 |
|
|
2024
Q1 | $29.4K | Sell |
18,500
-9,751
| -35% | -$14.5K | ﹤0.01% | 6124 |
|
|
2023
Q4 | $24.3K | Sell |
28,251
-1,385,825
| -98% | -$1.22M | ﹤0.01% | 6208 |
|
|
2023
Q3 | $1.51M | Buy |
1,414,076
+867,199
| +159% | +$1.79M | ﹤0.01% | 3770 |
|
|
2023
Q2 | $1.42M | Buy |
546,877
+7,015
| +1% | +$25K | ﹤0.01% | 3799 |
|
|
2023
Q1 | $2.2M | Sell |
539,862
-26,677
| -5% | -$123K | ﹤0.01% | 3476 |
|
|
2022
Q4 | $2.85M | Buy |
566,539
+32,642
| +6% | +$205K | ﹤0.01% | 3290 |
|
|
2022
Q3 | $6.98M | Sell |
533,897
-18,644
| -3% | -$282K | ﹤0.01% | 2445 |
|
|
2022
Q2 | $7.08M | Buy |
552,541
+18,620
| +3% | +$258K | ﹤0.01% | 2456 |
|
|
2022
Q1 | $8.14M | Sell |
533,921
-88,617
| -14% | -$1.38M | ﹤0.01% | 2578 |
|
|
2021
Q4 | $11M | Sell |
622,538
-4,580
| -0.7% | -$87.9K | ﹤0.01% | 2361 |
|
|
2021
Q3 | $13.2M | Buy |
627,118
+14,245
| +2% | +$314K | ﹤0.01% | 2138 |
|
|
2021
Q2 | $12.1M | Buy |
612,873
+437,541
| +250% | +$10.2M | ﹤0.01% | 2269 |
|
|
2021
Q1 | $5.1M | Sell |
175,332
-16,762
| -9% | -$469K | ﹤0.01% | 2959 |
|
|
2020
Q4 | $5.82M | Sell |
192,094
-10,920
| -5% | -$239K | ﹤0.01% | 2677 |
|
|
2020
Q3 | $3.27M | Sell |
203,014
-15,337
| -7% | -$280K | ﹤0.01% | 2891 |
|
|
2020
Q2 | $4.31M | Sell |
218,351
-25,091
| -10% | -$480K | ﹤0.01% | 2567 |
|
|
2020
Q1 | $3M | Sell |
243,442
-41,823
| -15% | -$683K | ﹤0.01% | 2659 |
|
|
2019
Q4 | $5.27M | Buy |
285,265
+283,025
| +12,635% | +$4.14M | ﹤0.01% | 2633 |
|
|
2019
Q3 | $31K | Buy |
2,240
+393
| +21% | +$5.9K | ﹤0.01% | 5315 |
|
|
2019
Q2 | $27K | Buy |
+1,847
| New | +$27K | ﹤0.01% | 5387 |
|
JP Morgan Chase's NGM Position: Q2 2024 in Review
JP Morgan Chase sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2024, closing a stake of 18,500 shares — an estimated $29.4K sold.
JP Morgan Chase first reported a position in NGM in Q2 2019 and held it in 20 quarters. The position peaked at $13.2M in Q3 2021. 0 funds tracked by Wall St. Rank hold NGM as of Q2 2024.
- JP Morgan Chase reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- JP Morgan Chase sold 18,500 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $29.4K.
- JP Morgan Chase first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 20 quarters.
- JP Morgan Chase's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $13.2M in Q3 2021.
- 0 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on JP Morgan Chase's 13F filing for Q2 2024, filed 12 Aug 2024.